BACKGROUND: Under inflammatory conditions, T cell-dependent (TD) protein antigens induce proinflammatory T- and B-cell responses. In contrast, tolerance induction by TD antigens without costimulation triggers the development of regulatory T cells. Under both conditions, IgG antibodies are generated, but whether they have different immunoregulatory functions remains elusive. OBJECTIVE: It was shown recently that proinflammatory or anti-inflammatory effector functions of IgG molecules are determined by different Fc N-linked glycosylation patterns. We sought to examine the Fc glycosylation and anti-inflammatory quality of IgG molecules formed on TD tolerance induction. METHODS: We administered chicken ovalbumin (OVA) with or without costimulus to mice and analyzed OVA-reactive IgG Fc glycosylation. The anti-inflammatory function of differentially glycosylated anti-OVA IgGs was further investigated in studies with dendritic cell cultures and in an in vivo model of allergic airway disease. Additionally, we analyzed the Fc glycosylation pattern of birch pollen-reactive serum IgGs after successful allergen-specific immunotherapy in patients. RESULTS: Stimulation with TD antigens under inflammatory conditions induces plasma cells expressing low levels of α2,6-sialyltransferase and producing desialylated IgGs. In contrast, plasma cells induced on tolerance induction did not downregulate α2,6-sialyltransferase expression and secreted immunosuppressive sialylated IgGs that were sufficient to block antigen-specific T- and B-cell responses, dendritic cell maturation, and allergic airway inflammation. Importantly, successful specific immunotherapy in allergic patients also induced sialylated allergen-specific IgGs. CONCLUSIONS: Our data show a novel antigen-specific immunoregulatory mechanism mediated by anti-inflammatory sialylated IgGs that are formed on TD tolerance induction. These findings might help to develop novel antigen-specific therapies for the treatment of allergy and autoimmunity.
BACKGROUND: Under inflammatory conditions, T cell-dependent (TD) protein antigens induce proinflammatory T- and B-cell responses. In contrast, tolerance induction by TD antigens without costimulation triggers the development of regulatory T cells. Under both conditions, IgG antibodies are generated, but whether they have different immunoregulatory functions remains elusive. OBJECTIVE: It was shown recently that proinflammatory or anti-inflammatory effector functions of IgG molecules are determined by different Fc N-linked glycosylation patterns. We sought to examine the Fc glycosylation and anti-inflammatory quality of IgG molecules formed on TD tolerance induction. METHODS: We administered chicken ovalbumin (OVA) with or without costimulus to mice and analyzed OVA-reactive IgG Fc glycosylation. The anti-inflammatory function of differentially glycosylated anti-OVA IgGs was further investigated in studies with dendritic cell cultures and in an in vivo model of allergic airway disease. Additionally, we analyzed the Fc glycosylation pattern of birch pollen-reactive serum IgGs after successful allergen-specific immunotherapy in patients. RESULTS: Stimulation with TD antigens under inflammatory conditions induces plasma cells expressing low levels of α2,6-sialyltransferase and producing desialylated IgGs. In contrast, plasma cells induced on tolerance induction did not downregulate α2,6-sialyltransferase expression and secreted immunosuppressive sialylated IgGs that were sufficient to block antigen-specific T- and B-cell responses, dendritic cell maturation, and allergic airway inflammation. Importantly, successful specific immunotherapy in allergicpatients also induced sialylated allergen-specific IgGs. CONCLUSIONS: Our data show a novel antigen-specific immunoregulatory mechanism mediated by anti-inflammatory sialylated IgGs that are formed on TD tolerance induction. These findings might help to develop novel antigen-specific therapies for the treatment of allergy and autoimmunity.
Authors: Constanze Hess; André Winkler; Alexandra K Lorenz; Vivien Holecska; Véronique Blanchard; Susanne Eiglmeier; Anna-Lena Schoen; Josephine Bitterling; Alexander D Stoehr; Dominique Petzold; Tim Schommartz; Maria M M Mertes; Carolin T Schoen; Ben Tiburzy; Anne Herrmann; Jörg Köhl; Rudolf A Manz; Michael P Madaio; Markus Berger; Hedda Wardemann; Marc Ehlers Journal: J Clin Invest Date: 2013-08-27 Impact factor: 14.808
Authors: J Stümer; M H C Biermann; J Knopf; I Magorivska; A Kastbom; A Svärd; C Janko; R Bilyy; G Schett; C Sjöwall; M Herrmann; L E Muñoz Journal: Clin Exp Immunol Date: 2017-06-13 Impact factor: 4.330
Authors: Alexandra Epp; Juliane Hobusch; Yannic C Bartsch; Janina Petry; Gina-Maria Lilienthal; Carolien A M Koeleman; Simon Eschweiler; Christian Möbs; Ashley Hall; Suzanne C Morris; Dominique Braumann; Christine Engellenner; Josephine Bitterling; Johann Rahmöller; Alexei Leliavski; Robina Thurmann; Mattias Collin; Kelley W Moremen; Richard T Strait; Véronique Blanchard; Arnd Petersen; Timo Gemoll; Jens K Habermann; Frank Petersen; Andreas Nandy; Helga Kahlert; Michael Hertl; Manfred Wuhrer; Wolfgang Pfützner; Uta Jappe; Fred D Finkelman; Marc Ehlers Journal: J Allergy Clin Immunol Date: 2017-07-18 Impact factor: 10.793